Journal
THROMBOSIS AND HAEMOSTASIS
Volume 121, Issue 7, Pages 976-978Publisher
GEORG THIEME VERLAG KG
DOI: 10.1055/a-1326-7028
Keywords
thrombosis; acute myocardial infarction; cardiology
Categories
Ask authors/readers for more resources
The article describes a case of thrombotic coronary side effect in a 72-year-old woman with advanced breast cancer following treatment with abemaciclib, highlighting the need to be cautious of potential cardiotoxic effects of new cancer treatment drugs.
The current article describes a 72-year-old woman who suffered an acute myocardial infarction due to plaque erosion (PE) 2 weeks after abemaciclib treatment onset due to advanced breast cancer. Abemaciclib is a cyclin-dependent kinase 4 and 6 inhibitor that has recently demonstrated efficacy and safety in advanced breast cancer. Of major concern, however, reported thromboembolic rates in randomized clinical trials testing this drug range from 0.6 to 5%. To the best of our knowledge this is the first thrombotic coronary side effect ever reported. We suggest that a treatment that increases thromboembolic risk, such abemaciclib, may have triggered PE in our patient, 15 days after abemaciclib initiation. New molecules are promising in cancer treatment; however, care must be paid to their potential cardiotoxic effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available